ArticleFrontiers in oncology2022

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.

Thomas Pasau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.